DDInter1139 DDInter899
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Mefenamic acid {u} (Compound) resembles {v} (Compound) Oxybenzone
Mefenamic acid {u} (Compound) binds {v} (Gene) CYP2C8
Mefenamic acid {u} (Compound) upregulates {v} (Gene) SUV39H1
Mefenamic acid {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Mefenamic acid {u} (Compound) downregulates {v} (Gene) DNAJA3
Mefenamic acid {u} (Compound) causes {v} (Side Effect) Somnolence
Mefenamic acid (Compound) resembles Ketoprofen (Compound)
Mefenamic acid (Compound) resembles Oxybenzone (Compound)
Mefenamic acid (Compound) binds CYP2C8 (Gene)
Mefenamic acid (Compound) upregulates SUV39H1 (Gene)
Mefenamic acid (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Mefenamic acid (Compound) downregulates DNAJA3 (Gene)
Mefenamic acid (Compound) causes Somnolence (Side Effect)